Ao.Univ.-Prof. Dr. Shuren LI, Physician for Internal Medicine and Nuclear Medicine
Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine)
Position: Associate Professor
ORCID: 0000-0001-7827-8051
shuren.li@meduniwien.ac.at
Research interests
Nuclear Medicine, Tumor imaging und biology, Tumor angiogenesis imaging, Receptor kinetics (in vitro and in vivo), Thyroid disease, Lipid metabolism
Grants
- Cooperative research on precise and personalized medicine: development of molecular imaging to guide targeted therapy (2016)
Source of Funding: OeAD (Agency for Education and Internationalisation), Scientific & Technological Cooperation with China (WTC AUSTRIA –CHINA)
Principal Investigator - The Evaluation of Tumorangiogenesis with I-123-VEGF-Receptor Scintigraphy in Patients with Glioblastoma (2006)
Source of Funding: OeNB (Oesterreichische Nationalbank), Anniversary Fonds of Austrian National Bank
Principal Investigator - VEGF: Implication in the Oncology (1995)
Source of Funding: OeNB (Oesterreichische Nationalbank), Anniversary Fonds of Austrian National Bank
Principal Investigator - Hans und Blanca Moser-Fonds „zur Förderung der Ausbildung von Krebs- und Herzspezialisten“ (1993)
Source of Funding: MedUni Vienna & University of Vienna, Moser-Fonds „zur Förderung der Ausbildung von Krebs- und Herzspezialisten“
Principal Investigator
Selected publications
- Li, S. et al. (2003) ‘Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy’, Annals of Oncology, 14(8), pp. 1274–1277. Available at: http://dx.doi.org/10.1093/annonc/mdg344.
- Li, S. et al. (2003) ‘111 In-DOTA-dPhe 1 -Tyr 3 -octreotide, 111 In-DOTA-lanreotide and 67 Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study’, European Journal of Nuclear Medicine and Molecular Imaging, 30(8), pp. 1087–1095. Available at: http://dx.doi.org/10.1007/s00259-003-1206-1.
- Rainer E., Wang H., Traub-Weidinger T, Widhalm G., Fueger B., Chang JL., Zhu ZH., Marosi C., Haug A., Hacker M., Li S.: The prognostic value of [123I] - Vascular Endothelial Growth Factor ([123I]-VEGF) in glioma. . Eur J Nucl Med Mol Imaging. 2018; 45(13):2396-2403. Available at: http://dx.doi.org/10.1007/s00259-018-4088-y11703..
- Li, S. et al. (2017) ‘The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab’, European Journal of Nuclear Medicine and Molecular Imaging, 44(10), pp. 1732–1741. Available at: http://dx.doi.org/10.1007/s00259-017-3724-2.
- Li Shuren, Peck-Radosavljevic M., Koller E., Koller F., Kaserer K., Kreil A., Kapiotis S., Hamwi A., Welch A.H., Valent P., P. Angelberger., Dudczak R. and Virgolini I.: Characterization of 123I-vascular endothelial growth factor binding sites expressed on tumour cells: Possible Implication for tumour scintigraphy. International J Cancer, 2001; 91:789-96. Available at: http://dx.doi.org/10.1002/1097-0215(200002)9999:9999<::aid-ijc1126>3.0.co;2-k.